Eurofins

UgenTec's FastFinder software platform uses artificial intelligence to enable analysis and interpretation of qPCR data, workflow automation, and genotyping.

CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.

By acquiring Bothell, Washington-based Blue Heron, Eurofins Genomics could strengthen its offerings to the synthetic biology market.

Transplant Genomics offers a test that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection.

Eurofins Scientific will help Adial validate a companion diagnostic for a drug being developed and identify patients for enrollment into a Phase III trial.

The addition of the Y chromosome detection will enable the firm to refine its already-approved MaternalFetalScreen T1 test to provide personalized risk assessment.

Eurofins will distribute Synthego's sgRNA products to its customers in 44 countries.

The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.

The system combines sample preparation technology capable of amplifying tens of thousands of locations in the genome with next-generation sequencing.